Rapamycin (Sirolimus)

Plain-language summary

An mTOR-inhibiting drug FDA-approved to prevent kidney transplant rejection and to treat LAM. It attracts off-label longevity interest from animal studies but is not FDA-approved for aging.

Regulatory status

Evidence snapshot

Preclinical only. Evidence comes from laboratory or animal studies. Effects in humans are unproven.

How it works

Inhibits the mTOR pathway (via binding FKBP-12), a central regulator of cell growth, metabolism, and autophagy; mTOR inhibition is the proposed basis for its lifespan effects in animals.

Approved uses and researched uses

Researched uses are studied but not FDA-approved and may be off-label. This is not a recommendation to use them.

Known risks and uncertainties

As an immunosuppressant it can increase infection risk and impair wound healing, and it can raise cholesterol/triglycerides, cause mouth ulcers, and affect blood counts. Its approved use carries significant monitoring requirements; low-dose intermittent longevity dosing is not standardized or proven safe long-term.

Cautions and contraindications

Hypersensitivity to sirolimus; significant caution with infections, planned surgery, and in combination with other immunosuppressants. Not established as safe for healthy people seeking longevity benefits.

Consumer considerations

• FDA approval is for transplant and LAM, not aging.
• Longevity evidence is largely from animals, not proven in humans.
• It is an immunosuppressant, so infection and healing risks are real.
• Off-label "low-dose weekly" longevity regimens are experimental and unstandardized.
• Requires clinician oversight and lab monitoring.

Questions to ask a licensed clinician

• What human evidence supports using this for aging, and how strong is it?
• How would immunosuppression affect my infection risk?
• What monitoring (labs, lipids, blood counts) would I need?
• How does it interact with my other medications and vaccinations?
• Do the uncertain benefits justify the risks for someone healthy?

Sources